Glide Pharma signs biologicals deal with major pharma company
Advertisement
Glide Pharma has signed an agreement with a pharmaceutical company to evaluate its proprietary Glide SDI(tm) - Solid Dose Injector - technology for the delivery of a branded peptide product. This is Glide Pharma's third deal involving a biological product, with further agreements close to fruition.
The deal is described as a future-directed relationship, focusing initially on one of the pharma company's branded biologicals; the new partner has also taken an option to enter into a full development programme. Under the terms of the deal, Glide Pharma will develop and test a range of solid dosage formulations of the branded peptide in the unique Glide SDI. These formulations will then be supplied to the partner company for further evaluation.